Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice

• DOI: 10.1038/srep26428
• Publication Date: 2016-05-26T09:42:46Z
• Authors: Linda A. Gallo; Micheal S. Ward; Amelia K. Fotheri...; Aowen Zhuang; Danielle J. Borg; Nicole B. Flemming; Ben M. Harvie; Toni L. Kinneally; Shang-Ming Yeh; Domenica A. McCarthy; Hermann Koepsell; Volker Vallon; Carol Pollock; Usha Panchapakesan; Josephine M. Forbes
• Keywords: Empagliflozin; Albuminuria

Abstract Blood glucose control is the primary strategy to prevent complications in diabetes. At onset of kidney disease, therapies that inhibit components renin angiotensin system (RAS) are also indicated, but these approaches not wholly effective. Here, we show once daily administration novel lowering agent, empagliflozin, an SGLT2 inhibitor which targets block reabsorption, has potential improve disease type 2 In male db / mice, a 10-week treatment with empagliflozin attenuated diabetes-induced upregulation profibrotic gene markers, fibronectin and transforming-growth-factor-beta. Other molecular (collagen IV connective tissue growth factor) histological (tubulointerstitial total collagen glomerular accumulation) benefits were seen upon dual therapy metformin. Albuminuria, urinary markers tubule damage (kidney injury molecule-1, KIM-1 neutrophil gelatinase-associated lipocalin, NGAL), growth, glomerulosclerosis, however, improved or metformin, plasma intra-renal activity was enhanced empagliflozin. this model, blood some fibrosis but, as per did provide complete renoprotection. Further research refine regimen diabetes nephropathy warranted.